Compare JPMorgan Chase & Co (JPM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs State Street SPDR S&P Biotech ETF — how do they compare? JPMorgan Chase & Co trades at $332.99 (market cap $880.98B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: JPMorgan Chase & Co is far larger — about 87.1× State Street SPDR S&P Biotech ETF's market cap, and JPMorgan Chase & Co pays a 1.99% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| JPM | XBI | |
|---|---|---|
Market Cap | $880.98B | $10.11B |
Volume | 7,721,661 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $365.18 | $169.55 |
52-Week Low | $282.84 | $104.99 |
Typical Hold Time | 127 Days | 38 Days |
Enterprise Value | $1.82T | — |
Dividend Yield | 1.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $331.42, up 0.56% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growing to $181.85B in 2025. The stock shows a P/E of 14.2 and ROE of 18.43%, supported by a 'Moderate Buy' analyst consensus and a $373.18 price target.
Outlook remains positive due to robust profitability and institutional confidence, though risks include geopolitical tensions and cybersecurity threats highlighted in recent news. The stock offers value with upside potential, but investors should monitor cash flow trends and macroeconomic headwinds.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
